NCT03908684

Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers

Recruiting now Last updated 13 December 2023

What this trial tests

trial testing Ultrasound Imaging in Prostate Cancer in 320 participants. Currently enrolling.

Timeline

17 December 2014

Primary endpoint
17 December 2025

17 December 2029

Quick facts

Lead sponsor	Sunnybrook Health Sciences Centre
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	320
Start date	17 December 2014
Primary completion	17 December 2025
Estimated completion	17 December 2029
Sites	1 location across Canada

Drugs / interventions tested

• Ultrasound Imaging

Conditions studied

• Prostate Cancer — all drugs for Prostate Cancer →
• Head and Neck Cancer — all drugs for Head and Neck Cancer →
• Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

Sunnybrook Health Sciences Centre — full company profile →

Who can join

Eligibility, any sex, with Prostate Cancer or Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our objective in this study is to identify an optimal ultrasound spectroscopy parameter that can be used as an early predictor of pathological complete or partial response in men with prostate cancer and men and women with rectum and head and neck cancers receiving treatment radiotherapy.

We have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo. The method can detect different forms of cell death and has been demonstrated to be sensitive to apoptotic, necrotic and mitotic cell death. The main goal, as described above, is to select the best ultrasound spectroscopy parameter to use as an early predictor of pathological complete response

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Ultrasound delta-radiomics during radiotherapy to predict recurrence in patients with head and neck squamous cell carcinoma.
   Fatima K, Dasgupta A, DiCenzo D, Kolios C, et al · · 2021 · cited 21× · PMID 33778174 · DOI 10.1016/j.ctro.2021.03.002
2. Current Role of Delta Radiomics in Head and Neck Oncology.
   Marcu DC, Grava C, Marcu LG. · · 2023 · cited 19× · PMID 36768535 · DOI 10.3390/ijms24032214
3. Quantitative ultrasound delta-radiomics during radiotherapy for monitoring treatment responses in head and neck malignancies.
   Tran WT, Suraweera H, Quiaoit K, DiCenzo D, et al · · 2020 · cited 19× · PMID 33235811 · DOI 10.2144/fsoa-2020-0073
4. Assessment of clinical radiosensitivity in patients with head-neck squamous cell carcinoma from pre-treatment quantitative ultrasound radiomics.
   Osapoetra LO, Dasgupta A, DiCenzo D, Fatima K, et al · · 2021 · cited 17× · PMID 33731738 · DOI 10.1038/s41598-021-85221-6
5. Application of Machine Learning Methods to Improve the Performance of Ultrasound in Head and Neck Oncology: A Literature Review.
   DeJohn CR, Grant SR, Seshadri M. · · 2022 · cited 14× · PMID 35158932 · DOI 10.3390/cancers14030665
6. Quantitative ultrasound radiomics in predicting recurrence for patients with node-positive head-neck squamous cell carcinoma treated with radical radiotherapy.
   Dasgupta A, Fatima K, DiCenzo D, Bhardwaj D, et al · · 2021 · cited 14× · PMID 33314716 · DOI 10.1002/cam4.3634
7. Quantitative US Delta Radiomics to Predict Radiation Response in Individuals with Head and Neck Squamous Cell Carcinoma.
   Osapoetra LO, Dasgupta A, DiCenzo D, Fatima K, et al · · 2024 · cited 5× · PMID 38391311 · DOI 10.1148/rycan.230029